
USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$4.19B
Market Cap
34.16
P/E Ratio
0.98
EPS
$33.64
52 Week High
$7.62
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $957M |
| Total Revenue | $1.2B |
| Cost Of Revenue | $231M |
| Costof Goods And Services Sold | $231M |
| Operating Income | $32M |
| Selling General And Administrative | $363M |
| Research And Development | $107M |
| Operating Expenses | $925M |
| Investment Income Net | - |
| Net Interest Income | -$18M |
| Interest Income | $23M |
| Interest Expense | $41M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $29M |
| Income Before Tax | $14M |
| Income Tax Expense | $11M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $3M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $55M |
| Ebitda | $84M |
| Net Income | $2M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.3B |
| Total Current Assets | $839M |
| Cash And Cash Equivalents At Carrying Value | $319M |
| Cash And Short Term Investments | $319M |
| Inventory | $178M |
| Current Net Receivables | $254M |
| Total Non Current Assets | $481M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $5M |
| Intangible Assets Excluding Goodwill | $5M |
| Goodwill | $2M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $1M |
| Other Current Assets | $87M |
| Other Non Current Assets | - |
| Total Liabilities | $1.7B |
| Total Current Liabilities | $939M |
| Current Accounts Payable | $63M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $28M |
| Total Non Current Liabilities | $728M |
| Capital Lease Obligations | $42M |
| Long Term Debt | $315M |
| Current Long Term Debt | $18M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $375M |
| Other Current Liabilities | $802M |
| Other Non Current Liabilities | $16M |
| Total Shareholder Equity | -$348M |
| Treasury Stock | - |
| Retained Earnings | -$454M |
| Common Stock | $62M |
| Common Stock Shares Outstanding | $133M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $36M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $29M |
| Capital Expenditures | $29M |
| Change In Receivables | - |
| Change In Inventory | -$45M |
| Profit Loss | - |
| Cashflow From Investment | $69M |
| Cashflow From Financing | -$102M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$173M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $2M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $957M |
| Total Revenue | $1.2B |
| Cost Of Revenue | $231M |
| Costof Goods And Services Sold | $231M |
| Operating Income | $32M |
| Selling General And Administrative | $363M |
| Research And Development | $107M |
| Operating Expenses | $925M |
| Investment Income Net | - |
| Net Interest Income | -$18M |
| Interest Income | $23M |
| Interest Expense | $41M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $29M |
| Income Before Tax | $14M |
| Income Tax Expense | $11M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $3M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $55M |
| Ebitda | $84M |
| Net Income | $2M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2016-06-16 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 0.095 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Indivior PLC is a leading biopharmaceutical company headquartered in North Chesterfield, Virginia, focused on developing innovative treatments for opioid dependence and related disorders. Known for its pioneering work with buprenorphine-based therapies, Indivior aims to improve patient outcomes and tackle the complexities associated with opioid use disorder. The company demonstrates a strong commitment to public health through substantial investments in research and development, reinforcing its position as a transformative leader in addiction treatment. With a comprehensive product portfolio and a dedicated patient-centric approach, Indivior is well-prepared to address the evolving challenges within the healthcare landscape.